Ophthalmic composition with hyaluronic acid

Abstract

An ophthalmic composition comprising a polymeric biguanide composition having less than 18 mol % of terminal amine groups and 55 mol % or greater of terminal guanidine groups as measured by 13 C NMR, and 0.005 w/v % to 0.04 w/v % hyaluronic acid. Alternatively, the ophthalmic composition comprises a polymeric biguanide composition comprising less than 18 mol % of terminal amine groups and 40 mol % or greater of terminal cyanoguanidino groups as measured by 13 C NMR, and 0.005 w/v % to 0.04 w/v % hyaluronic acid. The compositions can be used for cleaning, disinfecting or packaging a contact lens.

1 . An ophthalmic composition comprising:
 a polymeric biguanide composition comprising less than 18 mol % of terminal amine groups, and 55 mol % or greater of terminal guanidine groups as measured by  13 C NMR; and 0.005 w/v % to 0.04 w/v % hyaluronic acid.   
   
   
       2 . The composition of  claim 1  wherein the polymeric biguanide composition comprises less than 15 mol % of terminal amine groups, and 60 mol % or greater of terminal guanidine groups. 
   
   
       3 . The composition of  claim 2  wherein the polymeric biguanide composition comprises less than 10 mol % of terminal amine groups and 65 mol % or greater of terminal guanidine groups. 
   
   
       4 . The composition of  claim 1  wherein the weight ratio of hyaluronic acid to the polymeric biguanide composition in the composition is from 55:1 to 90:1. 
   
   
       5 . The composition of  claim 1  further comprising 0.01 wt. % to 0.8 wt. % of an amphoteric surfactant of general formula I 
     
       
         
         
             
             
         
       
       wherein R 1  is R or —(CH 2 ) n —NHC(O)R, wherein R is a C 8 -C 30 alkyl optionally substituted with hydroxyl and n is 2, 3 or 4; R 2  and R 3  are each independently selected from the group consisting of hydrogen and C 1 -C 4 alkyl; R 4  is a C 2 -C 8 alkylene optionally substituted with hydroxyl; and Y is CO 2   −  or SO 3   − . 
     
   
   
       6 . The composition of  claim 1  further comprising 1 ppm to 3 ppm polyquaternium-1. 
   
   
       7 . The composition of  claim 1  wherein the hyaluronic acid is obtained via a fermentation mixture comprising  Streptococcus equi.    
   
   
       8 . The composition of  claim 4  wherein the hyaluronic acid is present from 0.01 wt. % to 0.025 wt. %. 
   
   
       9 . The use of the composition of  claim 1  to clean, disinfect or package contact lenses, as a preservative in a pharmaceutical composition that includes a pharmaceutical agent, or as a preservative in a health care product. 
   
   
       10 . An ophthalmic composition comprising:
 a polymeric biguanide composition comprising less than 18 mol % of terminal amine groups and 40 mol % or greater of terminal cyanoguanidino groups as measured by  13 C NMR; and   0.005 w/v % to 0.04 w/v % hyaluronic acid, wherein the weight ratio of hyaluronic acid to the polymeric biguanide composition in the composition is from 55:1 to 90:1; and   an amphoteric surfactant of general formula I   
     
       
         
         
             
             
         
       
       wherein R 1  is R or —(CH 2 ) n —NHC(O)R, wherein R is a C 8 -C 30 alkyl optionally substituted with hydroxyl and n is 2, 3 or 4; R 2  and R 3  are each independently selected from the group consisting of hydrogen and C 1 -C 4 alkyl; R 4  is a C 2 -C 8 alkylene optionally substituted with hydroxyl; and Y is CO 2   −  or SO 3   − . 
     
   
   
       11 . The composition of  claim 10  wherein the polymeric biguanide composition comprises less than 15 mol % of terminal amine groups and 50 mol % or greater of terminal cyanoguanidino groups. 
   
   
       12 . The composition of  claim 10  wherein the polymeric biguanide composition comprises from 10 mol % to 30 mol % of terminal guanidine groups. 
   
   
       13 . The composition of  claim 10  wherein the hyaluronic acid is obtained via a fermentation mixture comprising  Streptococcus equi.    
   
   
       14 . The composition of  claim 10  wherein the hyaluronic acid is present from 0.01 wt. % to 0.025 wt. %. 
   
   
       15 . The use of the composition of  claim 10  to clean, disinfect or package contact lenses, as a preservative in a pharmaceutical composition that includes a pharmaceutical agent, or as a preservative in a health care product. 
   
   
       16 . A method of cleaning, disinfecting or packaging a contact lens comprising contacting said contact lens with the ophthalmic composition of  claim 1 . 
   
   
       17 . A method of cleaning, disinfecting or packaging a contact lens comprising contacting said contact lens with the ophthalmic composition of  claim 10 .